Clinical Trial

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possible to predict if patients will respond to treatment, and blood samples to look at the immune system response to study treatment. About 50 people will take part in this study. The study treatment will be given over an 8 week period and the investigators will continue to collect your health information for up to 5 years, as part of this study
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2016-02-17; most recent amendment 2026-04-07.
Status change: Recruiting → Active, Not Recruiting 2022-03-22
Status change: Not Yet Recruiting → Recruiting 2017-05-19
Trial Details
NCT Number NCT02688712
Lead Sponsor Providence Health & Services
Collaborators: Eli Lilly and Company
Conditions Rectal Adenocarcinoma
Enrollment 50 participants
Start Date 2016-03-24
Primary Completion 2026-01-26 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-13